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Aim. Search for compounds with antibacterial and antiviral properties among N-arylamides of 9-substituted
phenazine-1-carboxylic acids (PCA), inhibitors of the RNA synthesis. Methods. Influence of N-arylamides on
the RNA synthesis was tested in vitro in the model system of the DNA-dependent RNA polymerase of phage T7 (T7
RNAP). Antimicrobial activities of the N-arylamides against bacteria Erysipelothrix rhusiopathiae VR-2 var. IVM,
Klebsiella spp. and Escherichia coli ATCC25922 were investigated by the method of two-fold dilution in a liquid
medium. Antiviral effects against Bovine Viral Diarrhea Virus (BVDV) and cytotoxicity of the N-arylamides were
evaluated using Madin-Darby bovine kidney (MDBK) cells. Results. Twenty N-arylamides appeared to be
efficacious inhibitors of the RNA synthesis at concentrations of 0.48–61 µÌ. The compound 16 proved to be the
most effective inhibitor of T7 RNAP with the IC50 value being 0.48 µÌ. Fourteen N-arylamides demonstrated
antibacterial properties against gram positive and gram negative bacteria at the 0.1–10 µg/ml concentrations. A
number of the N-arylamides revealed a multiplicity of their antimic- robial actions: 7 compounds against two
bacteria and two compounds, 2 and 3, against three bacteria investigated. N-arylamides 16 and 26 showed high
inhibitory activity as to BVDV with the IC
50
values 0.43 and 0.88 µg/ml and SI values 160 and 10
correspondingly. Conclusions. The obtained data evidence that the most likely targets of the N-arylamides
9-substituted PCA in bacteria and viruses are their RNA synthesizing complexes.
Keywords: N-arylamides 9-substituted PCA, model system of the DNA-dependent RNA-polymerase of phage T7,
antibacterial activity, antiviral activity.
Introduction. At the end of the 20th century the occu-
rrence and spreading of the agents of new dangerous
infectious diseases (HIV, rotaviruses, Ebola virus and
Marburg virus, Hantaviruses, SARS, avian influenza
virus H5N1, etc.) [1, 2] as well as new strains of the
known microorganisms and viruses, getting resistant to
modern clinical preparations, triggered the search for
new biologically active compounds – potential thera-
peutic agents.
From this standpoint the heteroaromatic tricycle
compounds, especially their carboxylic acids and
amids, attract pharmacologists and medical chemists
who consider them as the promising basis to create the
databases of biologically active compounds.
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In the previous work [3] we revealed a wide spec-
trum of antibacterial features of N-arylamides of
phenazine-1-carboxylic acids (PCA-1). About 20
compounds demonstrated high antituberculosis activity
towards museum and clinical strains of Mycobacterium
tuberculosis. They included efficient inhibitors of a
number of gram-positive bacteria, in particular – Sta-
phylococcus aureus, Bacillus cereus, Micrococcus sp.
and Erysipelothrix rhusiopathiae (the collection of the
Institute of Veterinary Medicine, NAAS of Ukraine)
[4].
It should be noted that the presence of carboxamide
fragment conditions the potential conformational fle-
xibility of N-arylamides of PCA-1. The conformational
motility of these compounds promotes their efficient
steric adjustment for the interaction with “homolo-
gous” enzymatic targets of the pathogenic agents and/
or their resistant strains. This structural characteristic is
important for the design of inhibitors with potential
multiplex activity or inhibitors-agents, which are ca-
pable of fast mutating and acquiring resistance to cli-
nical preparations. Noteworthy that the structural fle-
xibility of non-nucleoside inhibitors of reverse tran-
scriptase HIV Delavirdine and Etravirine [5–7] is the
reason of preserving their antiviral activity regarding
the resistant strains of HIV.
It is known that the substitution of “peri-position”
of phenazine heterocycle (i.e. the position, adjoining
the nitrogen atom) is vital for the biological activity of
PCA-1 derivatives. For instance, lomofungin (the ether
of multisubstituted PCA-1 with the hydroxyl group in
position 9) is one of the preparations of wide anti-
microbial activity [8]. The works [9, 10] show that the
nature of the substitute in position 9 is highly relevant
for N-alkylamides of monosubstituted PCA-1 as it
impacts the level of their antitumor activity.
Taking into consideration the abovementioned pro-
mising characteristics of arylamides PCA-1 as well as
the decisive significance of the substitution in the
heterocycle for the biological activity of the com-
pounds, we synthesized two new series of
N-arylamides of 9-methyl and 9-methoxyphena-zine-
1-carboxylic acids (Fig. 1) [11].
Phenazine antibiotics are remarkable for the mul-
tiplex mechanism of their biological activity. They
easily penetrate the bacterial cell and join the
oxidation-reduction processes [12, 13], transforming
into relatively stable anions, which generate the
formation of active oxygen forms (O2, OH
– and H2O2).
It inhibits the functioning of superoxide dismutase and
causes the induction of oxidative stress and death of
the microorganisms. In addition, the planar aromatic
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Fig. 1 The structures of investigated
9-substituted PCA-1 amides
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derivatives of phenazine – antibiotics iodinine, muxin,
pyocyanin – are capable of interacting with DNA/RNA
[14]. It was also demonstrated that phenazine antibio-
tics inhibit DNA-dependent synthesis of RNA not only
due to the blocking of the DNA-matrix via intercala-
tion, but also due to the interaction with RNA-poly-
merase and/or ribonucleoside-3’-phosphates [15–17].
Therefore, we selected an easy-to-use and produ-
ctive transcription system on the basis of DNA-
dependent RNA-polymerase of phage T7 (RNAP T7)
for the purpose of screening synthesized compounds
and selecting RNA synthesis inhibitors. This model
system was successfully used to reveal efficient
inhibitors of transcription – antimicrobial and/or anti-
viral agents [18–20]. The preliminary testing of aryla-
mides of 9-substituted PCA-1 in the abovementioned
model system demonstrated reliable inhibition of RNA
synthesis by a number of compounds at the concen-
tration of 25 µg/ml (~80 µM) [11].
The current work was aimed at thorough inve-
stigation of the concentration-dependent influence of
9-substituted PCA-1 carboxamides on RNA synthesis
to detect the effective transcription inhibitors, to study
their antimicrobial and antiviral properties and to
determine the structure-activity relationship.
Materials and Methods. The investigated PCA-1
phenylamides were synthesized by the methods, des-
cribed in [11]. All the calculations, including the opti-
mization of ligand geometry, were accomplished
using QXP/Flo+ software package. The docking was
performed using a flexible ligand and a stable receptor
model [11].
The compounds for biological studies were dis-
solved in 100% DMSO up to the concentration of stock
solutions of 100 µg/ml.
In vitro transcription assay. The influence of the
synthesized compounds on RNA synthesis was tested
in RNAP T7 system by the method [described in] [5],
using the commercial reagents of Fermentas (Lithua-
nia). The transcription was performed in 20 µl of the
reaction mixture, containing 0.5 µg of the linearized
plasmid DNA pTZ19R, 2 mM ribonucleoside triphos-
phates, 20 units of the active inhibitor of RNAses Ribo-
LockTM in the presence of the following substances (in
mM): tris-HCl – 40, pH 7.9, MgCl2 – 6, spermidine – 2,
NaCl – 10, DTT – 10 and 12 units of active RNA-
polymerase of phage T7. The studied substances were
dissolved in DMSO (1 mg/ml) and added to the reaction
mixture in the amount of 0.5 µl. DMSO concentration
in the control and experiment samples was 2.5%. The
reaction mixture was kept at 37°C for 45 min and the
reaction was terminated by cooling (–20°C).
The reaction products were detected by gel-elec-
trophoresis in 1.2% agarose with ethidium bromide in-
cluded in the gel. RNA-transcripts were visualized on
transilluminator in UV-light with subsequent photo-
graphing [of] the electrophoregrams with a digital
camera.
The inhibiting activity of test-agents was determi-
ned by comparing the amount of the obtained RNA-
product with the control (the amount of RNA-product
without the inhibitor). The value of IC50 (the inhibitor
concentration, required for the 50%-inhibition of the
enzymatic activity) was determined via densitometry,
evaluating the intensity of electrophoretic stripes using
Scion Image for Windows, Release Beta 4.0.3 soft-
ware.
Microbiological studies. The strains of microorga-
nisms from the collection of the Institute of Veterinary
Medicine, NAAS, E. rhusiopathiae VR2 var. IVM,
Klebsiella spp. and Escherichia coliATCC 25922 were
used in the work. Pure test-cultures of bacteria were
obtained by plating them on solid nutrient medium with
further incubation for 24 h. After the microscopic
control the colonies of microorganisms were suspended
in the physiological solution until 0.5 turbidity level by
McFarland standard.
The antimicrobial activity of 9-substituted PCA-1
phenylamides was studied by the method of two-fold
dilution in a liquid medium of Muller-Hinton and BHI
broth (BioMeriex, France), prepared following the
manufacturer’s instructions in 96-vial plates [21–23].
Previously prepared sterile plates (Sarstedt, Ger-
many) were filled up with 140 µl of the medium with
the addition of 50 µl of suspension of the test-micro-
organism in the final concentration of 1·107 of the
colony-forming units (CFU) in one cubic centimeter,
and 10 µl of test substances (in DMSO solvent) in
corresponding concentrations; then the incubation was
carried out for 18–24 h at 36.7 ± 0.3°C.
The vials with the corresponding liquid medium
and microorganism culture but without the test-agent
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served as a control.Only DMSO was added to some
vials instead of the test-substance solution to control the
toxicity. Two vials were used for all concentrations of
each sample and control. The results were visually
registered by the presence of evident growth of the
bacterial culture.
The minimal inhibiting concentration (MIC) was
determined as the least concentration of the anti-
microbial agent, inhibiting the evident growth of the
microorganism test-culture completely.
Cytotoxicity test. The cytotoxicity (CC50) was
evaluated using the monolayer line of transplanted
culture of Madin-Darby bovine kidney (MDBK) cells,
previously tested by the method of polymerase chain
reaction (PCR) for the micoplasm contamination. The
cell culture was cultivated on the nutrient medium
RPMI-1640 Sigma-Aldrich (USA) with 10% heat-ina-
ctivated fetal bovine serum (Sigma-Aldrich), penicillin
and streptomycin (100 IU/ml [each) or kanamycin (50
IU/ml) in 96-vial plates of Nunc Company (Denmark)
in the atmosphere with 5% CO2. The monolayer of
cells, formed in vials 24 h later, was washed and the
supporting non-serum medium with the corresponding
concentration of the investigated compound was added
to the vials. The supporting medium with the solvent
(DMSO) was added to the control vials.
The registration of results was performed daily for
120 h (Leica DMIL microscope, Germany), observing
the monolayer of MDBK cell culture – the presence or
absence of their degeneration, or the change in their
morphology. The concentration was considered to be
cytotoxic when the number of living cells decreased by
50%.
The antiviral activity of preparations was studied
using the bovine viral diarrhea virus (BVDV) which is a
typical surrogate model for the hepatitis C virus (HCV)
while studying the impact of antiviral preparations, as
its structural genes are similar to those of HCV and it
can be reproduced in vitro [24]. To determine the
efficient inhibiting concentration EC50 (the lowest
concentration of the preparation, when 50% of infected
cell samples had the infectious titer of the virus,
reduced by 1.75–2.0 lgID50), the test-virus in the dose of
100 TCD50/0.1 ml was introduced into MDBK cell
culture and incubated for 1 h at 37°C. After the
adsorption of the virus on the cells for 1 h it was
extracted and the cells were washed with the nutrient
medium. Then the preparations in different concentra-
tions were introduced into the supporting medium
(RPMS-1640 + 2% fetal serum). The virus reprodu-
ction was determined by the special cytopathogenic
activity and the infectious titer for each concentration
of the preparation.
Results and Discussion. Our previous work pre-
sented detailed description of obtaining two series of
new N-arylamides of 9-methyl and 9-methoxy-PCA-1
[11]. In total we synthesized 26 compounds for
biological testing. The aryl fragments of both series of
compounds were presented by aromatic systems with
different exocyclic groups (CH3, CF3, (CH2)3CH3, Cl
and other substitutes) in certain ring positions.
DMSO is known for its vivid antimicrobial
properties [25]. Taking this fact into consideration we
determined the concentration dependence of the
DMSO inhibitory activity with regard to the bacterial
test-cultures for further objective evaluation of the
antibacterial activity of the investigated compounds. It
was established that DMSO in the concentration range
of 5–10% demonstrates its toxic impact on all the
test-cultures, while the concentration of 2.5% has no
evident impact on the growth of the investigated
bacteria compared to the control of culture growth.
Table 1 presents the results of the enzymatic and
antimicrobial screening of the synthesized compounds.
It is evident that 20 compounds efficiently inhibit the
RNA synthesis in the transcriptional system for RNAP
T7 in the range of 0.48–63 µM. n-butylphenylamide
9-methyl-PCA-1 (16) with ²Ñ50 = 0.48 µM proved to be
the most efficient. High activity level was also
demonstrated by pyridine (4-il)amide (23) and ì-car-
bomethoxyphenylamide (25) of 9-methyl-substituted
PCA-1 with IC50 value of 9.6 and 16.2 µM, res-
pectively.
The impact of the substitute in position 9 of phena-
zine heterocycle on the ability of inhibiting RNA syn-
thesis may be traced by comparing the activity of com-
pounds with the same arylamide fragments. For insta-
nce, it was established that 9-methyl-phenazines with
methyl and trifluoromethyl substitutes in different posi-
tions of phenylamides are much more active compared
to analogous 9-methoxy substitutes. Regardless of the
nature of the substitute, the compounds with substitutes
in ortho-position of the phenylamide fragment
demonstrated their ability of inhibiting RNA synthesis.
Instead, the activity of meta- and para-substituted
compounds was greatly depen- dent on both the nature
of the substitute in the aryl- amide fragment and the
substitute in position 9 of phe- nazine.
The initial screening of the antibacterial activity
was performed at the concentration of 100 µg/ml. The
obtained active compounds were tested in the range of
100–01 µg/ml with consecutive 10-fold dilution.
Gram-positive bacteria E. rhusiopathiae VR-2 var.
IVM appeared to be sensitive to 12 investigated
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No. of
compou
nd
E. rhusiopathiae VR-2 var. IVM Klebsiella spp. E. coli ATCC25922 ÐÍÊÏ Ò7
100 g/ml MIC, g/ml 100 g/ml MIC, g/ml 100 g/ml MIC, g/ml IÑ50, M ( g/ml)
1 + 0,1 – – – – >100 (>25)
2 + 1 + 10 + 10 30,4 (10)
3 + 0,1 + 1 + 10 45 (15)
4 + – – – – – > 80 (> 25)
5 + 1 + 1 – – > 80 (> 25)
6 – – + 10 + 10 31,2 (12)
7 + 1 – – + 0,1 63 (25)
8 – – + 1 – – 25,2 (10)
9 – – – – + – > 80 (> 25)
10 – – – – – – 55 (20)
11 + 1 + 1 + 100 37,8 (9)
12 + 100 + 1 – – 38,3 (12)
13 + 1 + 1 – – 32,1 (10,5)
14 + 1 + 100 – – 26 (8,5)
15 – – – – – – > 80 (> 25)
16 – – – – – – 0,48 (0,17)
17 – – – – – – 36,7 (14)
18 – – – – – – 28,9 (11)
19 – – – – – – 32,8 (12,5)
20 – – + 1 + 10 57,4 (20)
21 – – – – – – 28,7 (9)
22 + 100 + 10 + 1 61 (20)
23 – – – – + 100 9,6 (3)
24 – – – – + 100 > 80 (> 25)
25 – – + 100 + – 16,2 (6)
26 – – – – – 100 33,8 (12)
Table 1
The results of enzymatic and antimicrobial screening of PCA-1 phenylamides
compounds at 100 µg/ml. The highest activity against
bacteria of this strain was demonstrated by 9-metho-
xy-PCA-1 (1) and its ortho-tolyl amide (3). At 0.1
µg/ml they were capable of almost complete inhibition
of the microorganism growth. Seven compounds, na-
mely, phenylamide (2) para-tolyl amide (5) and ortho-
trifluoromethyl phenylamide (7) out of the series of
9-methoxy-substituted PCA-1, initial acid (11) and
three tolyl amides (13–15) out of the series of 9-methyl-
PCA-1 turned out to be active at 1 µg/ml (Table 1).
A considerable number of the investigated test-
agents proved to be efficient inhibitors of gram-nega-
tive bacteria. For instance, in the abovementioned con-
centration range 10 phenylamides of 9-substituted PCA-1
were efficient inhibitors of the growth of bacteria Kleb-
siella spp., and six phenylamides inhibited the growth
of bacteria E. coli ATCC25922. Here phenylamide (2),
ortho-tolyl amide (3) and para-butylphenylamide (6)
of 9-methoxy-PCA-1 inhibited the growth of both
gramnegative bacteria. According to the results obtain-
ed, the most promising investigated compounds are phe-
nylamide (2) and ortho-tolyl amide (3) of 9-methoxy-
PCA-1, efficiently blocking the growth of all the test
cultures, used by us.
The fact of inhibiting the growth of microbial
agents by one and the same substance may be explained
by acting on the functionally identical cellular targets.
This assumption is based on the fact that 3D structures
of different DNA and RNA-polymerases are highly
homologous, contain the same structural domains and
conservative motives, required for the elongation of the
nucleic acid chain [26, 27]. Therefore, one may
anticipate that a substance, binding to the conservative
elements of the corresponding enzyme complex and
blocking its functional activity, is capable of inhibiting
the work of other representatives of this superfamily of
enzymes, but the degree of inhibition is likely to vary.
Although there was not found a direct correlation
between the inhibitory activity of substances in the
model enzymatic and bacterial systems (because of ind-
ividual peculiarities of bacterial transcriptional comple-
xes and some other factors), the reliable inhibition of
RNA synthesis, established by us in the model system
RNAP T7 by the compounds, actively inhibiting the
growth of bacteria, allows the assumption that
RNA-synthesizing complex is a probable cell target.
It is possible to predict the antiviral activity of the
compounds of this series, at least due to their ability of
inhibiting the viral enzyme – RNA-polymerase of pha-
ge T7, as the bacteriophages are viruses of bacteria
[28], and phage T7 is considered to be a surrogate mo-
del of DNA viruses without a supercapside [29].
There were two reasons of our selection of BVDV
model to test the antiviral activity of phenylamides.
Firstly, BVD is one of most common veterinary infe-
ctions, causing serious health problems for animals and
leading to considerable economic losses [30]. Seco-
ndly, the virus belongs to the pestiviruses of Flavivi-
ridae family and its cellular model is used as a surrogate
model of HCV [31] for the selection of compounds,
inhibiting its reproduction.
To evaluate antiviral properties and to establish the
connection between the functional activity and the stru-
cture of phenylamides the testing required three para--
butylphenylamides – compounds 6, 16 and 26, as the
work [19] demonstrated that the introduction of the bu-
tyl substitute into the benzol fragment of the molecule
of 3-oxo-1,2,4-[5,6-b][1,4]-benzothiazine leads to reli-
able enhancement of the ability of this compound to
inhibit RNA synthesis in the T7 RNAP transcription
system compared to trifluoromethyl-substituted deri-
vative.
The antiviral properties of phenylamides 6, 16, and
26 were evaluated, analyzing the level of their impact
on the eukaryotic cells in MDBK culture. The results of
the investigations are presented in Table 2. It was
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No. of compound
BVDV/MDBK cell culture
S²
RNAP T7
²Ñ50, µM CC50, µM EC50, µM
6 64,9 – – 31,2
16 67,2 0,42 160 0,48
26 8,8 0,88 10 33,8
Table 2
The results of studies on antiviral activity of PCA-1 para-butylphenylamides
established that the nature of 9-substitute has
significant impact on both the toxicity and the antiviral
properties of the abovementioned compounds. For
instance, para-butylphenylamide 26 demonstrated a
high activity with EC50 = 0.88 µM. The introduction of
a hydrophobic methyl group into position 9 of the
phenazine heterocycle caused the increase in the
activity of para-butylphenylamide 16 which demon-
strated the highest activity with EC50 = 0.42 µM.
Instead, the substitution of the methyl group by the
methoxy-group in position 9 leads to practically
complete loss of the antiviral activity of the corres-
ponding para-butylphenylamide 6.
The chemotherapeutic index, or selectivity index
(XTI = SI), is calculated as CC50 to EC50 ratio. The
compounds with XTI (SI) = 4 or more are considered to
be active. It is noteworthy, that the higher SI, the safer
and more efficient the investigated test-agent.
High antiviral impact of amides 16 and 26 corre-
lates with the results [11], which demonstrate that con-
formationally labile butyl “tail” of these compounds is
capable of stabilizing the transcriptional complex
RNAP T7 [11], filling in the residual volume of the
catalytic socket, restricted by the residues of
aminoacids Lys441 and Ile810 (Fig. 2), while 9-methyl
group of phenylamide 16 is fixed in the narrow
hydrophobic socket, common for many DNA-depen-
dent RNA-polymerases [32].
The interaction of the ligand and the amino acid
environment of this socket may have considerable
impact on the functioning of the enzyme and govern the
level of inhibitory properties of the ligand. The con-
figuration of the location of para-butylphenylamide 6
is realized in the transcriptional complex RNAP T7,
“reversed” due to the configuration of phenylamides
16 and 26 (Fig. 2), which may be related to the
excessive volume and polarity of 9-methoxy-group of
compound 6. The realization of the important hydrogen
bond between the amide proton and the carbonyl group
of Asp812 requires evident exit of the amide bond of
compound 6 from the plane of the basic phenazine
heterocycle, compared to the compounds 16 and 26,
which is accompanied by the decrease in conjugation
in the structure.
These differences in the structure of model
complexes of the RNAP T7 catalytic socket with
compounds 6, 16 and 26 are likely to condition the
difference in their antiviral properties.
Therefore, taking the abovementioned into
consideration, phenylamides 16 and 26, with XTI
values of 160 and 10, respectively, appear to be quite
promising inhibitors of BVDV.
It is noteworthy that compound 16 demonstrated
the most efficient inhibitory activity regarding both
RNA synthesis in the model system of RNAP T7
transcription, and in BVDV model.
These results are promising for further study of the
investigated compounds activity against other viral
infections, including HCV on both cellular and animal
models.
Conclusions. It was shown that N-arylamides of
9-substituted PCA-1 are a promising class for the
elaboration of efficient antimicrobial preparations.
The study of their biological activity in vitro re-
vealed a number of antibacterial compounds with rather
a high activity regarding gram-positive and gram-
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Fig. 2 The location of compounds 6, 16 and 26 in the model of the active site of RNAP T7 (the data, obtained by the molecular docking [11])
negative bacteria with MIC values in the range of
0.1–10 µg/ml. The multiple activity against bacterial
test-systems was established for some compounds.
Two arylamides (16 and 26) demonstrated efficient
activity against BVDV (IC50 = 0.42 and 0.88 µM) with
high XTI values (160 and 10, respectively). It should be
noted that all the arylamides with antibacterial and anti-
viral properties are blocking RNA synthesis reliably in
the model system of RNAP T7 transcription, which was
generally more sensitive to arylamides of 9-methyl
PCA-1. The activity of compounds also depends on the
nature and position of the substitute in the arylamide
fragment.
The data obtained are one more confirmation of the
reasonable application of the abovementioned model
system for the primary selection of RNA synthesis
inhibitors – potential antibacterial and antiviral agents.
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Ìåòà. Ïîøóê ñåðåä N-àðèëàì³ä³â 9-çàì³ùåíèõ ôåíàçèí-1-êàðáî-
íîâèõ êèñëîò (ÔÊÊ-1) – ³íã³á³òîð³â ñèíòåçó ÐÍÊ – ñïîëóê ç àíòè-
áàêòåð³éíèìè òà àíòèâ³ðóñíèìè âëàñòèâîñòÿìè. Ìåòîäè.
Âïëèâ N-àðèëàì³- ä³â íà ñèíòåç ÐÍÊ in vitro âèçíà÷àëè ³ç çàñòîñó-
âàííÿì ìîäåëüíî¿ ñèñòåìè ÄÍÊ-çàëåæíî¿ ÐÍÊ-ïîë³ìåðàçè áàê-
òåð³îôàãà Ò7; àíòèì³êðîáíó àêòèâí³ñòü N-àðèëàì³ä³â –
ìåòîäîì äâîðàçîâèõ ðîçâåäåíü ó ð³äêîìó ñåðåäîâèù³ ïðîòè áàê-
òåð³é Erysipelothrix rhusiopathiae VR-2 var. IVM, Klebsiella spp. òà
Escherichia coli ATCC25922. Àíòèâ³ðóñíó ä³þ ùîäî â³ðóñó áè÷à÷î¿
â³ðóñíî¿ ä³àðå¿ (ÂÁÂÄ) ³ öèòîòîêñè÷í³ñòü N-àðèë- àì³ä³â îö³íþ-
âàëè íà ïåðåùåïëþâàí³é ë³í³¿ êóëüòóðè êë³òèí íèðêè òåëÿòè. Ðå-
çóëüòàòè. Äâàäöÿòü N- àðèëàì³ä³â âèÿâèëèñÿ åôåêòèâíèìè
³íã³á³òîðàìè ñèíòåçó ÐÍÊ ó ìåæàõ êîíöåíòðàö³é 0,48–63 ìêÌ.
Íàé- âèùó àêòèâí³ñòü ïðîäåìîíñòðóâàëà ñïîëóêà 16, ²Ñ50 ÿêî¿
ñòàíîâèòü 0,48 ìêÌ. Àíòèáàêòåð³éí³ âëàñòè- âîñò³ ñòîñîâíî
ãðàìïîçèòèâíèõ ³ ãðàìíåãàòèâíèõ áàêòåð³é ïðîÿâèëè 14 N-àðè-
ëàì³ä³â ïðè êîíöåíòðàö³ÿõ 0,1– 10 ìêã/ìë. Äëÿ íèçêè N-àðèëàì³ä³â
âñòàíîâëåíî ìíîæèííèé õàðàêòåð àíòèáàêòåð³éíî¿ ä³¿: ñ³ì ñïî-
ëóê ïðîòè äâîõ ³ äâ³ (2 ³ 3) – ïðîòè òðüîõ äîñë³äæóâàíèõ áàêòåð³é.
N-àðèëàì³äè 16 ³ 26 âèÿâèëè âèñîêó ³íã³á³òîðíó çäàòí³ñòü ïðîòè
ÂÁÂÄ ç ïîêàçíèêàìè ²Ñ50 0,43 ³ 0,88 ìêÌ ³ S² > 160 ³ 10 â³äïîâ³äíî.
Âèñíîâêè. Îòðèìàí³ ðåçóëüòàòè äàþòü ï³äñòàâó ââàæàòè, ùî
â³ðîã³äíèìè ì³øåíÿìè äëÿ N-àðèëàì³ä³â 9-çàì³ùåíèõ ÔÊÊ-1 ó
áàêòåð³é ³ â³ðóñ³ìîæóòü áóòè º ¿õí³ ÐÍÊ-ñèíòåçóâàëüí³ êîìïëåê-
ñè.
Êëþ÷îâ³ ñëîâà: N-àðèëàì³äè 9-çàì³ùåíèõ ÔÊÊ-1, ìîäåëüíà
ñèñòåìà òðàíñêðèïö³¿ ôàãà Ò7, àíòèáàêòåð³éíà àêòèâí³ñòü, àí-
òèâ³ðóñíà àêòèâí³ñòü.
Ë. È. Ïàëü÷èêîâñêàÿ, Î. Â. Âàñèëü÷åíêî, Ì. Î. Ïëàòîíîâ,
Â. Ã. Êîñòèíà, Ì. Ì. Áàáêèíà, Î. À. Òàðàñîâ, Ä. Á. Ñòàðîñèëà,
Ñ. Ï. Ñàìîéëåíêî, Ñ. Ë. Ðèáàëêî, Î. Ì. Äåðÿáèí, Ä. Í. Ãîâîðóí
Îöåíêà àíòèáàêòåðèàëüíîé è àíòèâèðóñíîé àêòèâíîñòè
N-àðèëàìèäîâ 9-çàìåùåííûõ ÔÊÊ-1 – èíãèáèòîðîâ
ìîäåëüíîé òðàíñêðèïöèè ôàãà Ò7
Öåëü. Ïîèñê ñðåäè 9-çàìåùåííûõ N-àðèëàìèäîâ ôåíàçèí-1-êàð-
áîíîâîé êèñëîòû (ÔÊÊ-1) – èíãèáèòîðîâ ñèíòåçà ÐÍÊ – ñîåäè-
íåíèé ñ àíòèáàêòåðèàëüíûìè è àíòèâèðóñíûìè ñâîéñòâàìè.Ìå-
òîäû. Âëèÿíèå N-àðèëàìèäîâ íà ñèíòåç ÐÍÊ in vitro îïðåäåëÿëè ñ
èñïîëüçîâàíèåì ìîäåëüíîé ñèñòåìû ÄÍÊ-çàâèñèìîé ÐÍÊ-ïîëè-
ìåðàçû áàêòåðèîôàãà Ò7; àíòèìèêðîáíóþ àêòèâíîñòü N-àðèë-
àìèäîâ – ìåòîäîì äâóêðàòíûõ ðîçâåäåíèé â æèäêîé ñðåäå ïðî-
òèâ áàêòåðèé Erysipelothrix rhusiopathiae VR-2 var. IVM, Klebsiel-
la spp. è Escherichia coli ATCC25922. Àíòèâèðóñíîå äåéñòâèå ïî
îòíîøåíèþ ê âèðóñó áû÷üåé âèðóñíîé äèàðåè (ÂÁÂÄ) è öèòîòîê-
ñè÷íîñòü N-àðèëàìèäîâ îöåíèâàëè íà ïåðåâèâàåìîé ëèíèè êóëüòó-
ðû êëåòîê ïî÷êè òåëåíêà. Ðåçóëüòàòû. Äâàäöàòü N-àðèëàìèäîâ
îêàçàëèñü ýôôåêòèâíûìè èíãèáèòîðàìè ñèíòåçà ÐÍÊ â äèàïàçî-
íå êîíöåíòðàöèé 0,48–63 ìêÌ. Íàèâûñøóþ àêòèâíîñòü ïðîäåìîí-
ñòðèðîâàëî ñîåäèíåíèå 16, ²Ñ50 êîòîðîãî ñîñòàâëÿåò 0,48 ìêÌ.
Àíòèáàêòåðèàëüíûå ñâîéñòâà îòíîñèòåëüíî ãðàìïîçèòèâíûõ è
ãðàìíåãàòèâíûõ áàêòåðèé ïðîÿâèëè 14 N-àðèëàìèäîâ â êîíöåíò-
ðàöèÿõ 0,1–10 ìêã/ìë. Äëÿ ðÿäà N-àðèëàìèäîâ óñòàíîâëåí ìíî-
æåñòâåííûé õàðàêòåð àíòèáàêòåðèàëüíîãî äåéñòâèÿ: ñåìü ñîå-
äèíåíèé ïðîòèâ äâóõ, à äâà (2 è 3) – ïðîòèâ òðåõ èññëåäóåìûõ
áàê- òåðèé. N-àðèëàìèäû 16 è 26 âûÿâèëè âûñîêèé èíãèáèòîðíûé
ïîòåíöèàë ïðîòèâ ÂÁÂÄ ñ ïîêàçàòåëÿìè ²Ñ50 0,43 è 0,88 ìêÌ è S²
> 160 è 10 ñîîòâåòñòâåííî. Âûâîäû. Ïîëó÷åííûå ðåçóëüòàòû
äà- þò îñíîâàíèå ïîëàãàòü, ÷òî âîçìîæíûìè ìèøåíÿìè äëÿ
N-àðèë- àìèäîâ 9-çàìåùåííûõÔÊÊ-1 ó áàêòåðèé è âèðóñîâ ìîãóò
áûòü èõ ÐÍÊ-ñèíòåçèðóþùèå êîìïëåêñû.
Êëþ÷åâûå ñëîâà: N-àðèëàìèäû 9-çàìåùåííûõ ÔÊÊ-1, ìîäåëü-
íàÿ ñèñòåìà òðàíñêðèïöèè ôàãà Ò7, àíòèáàêòåðèàëüíàÿ àêòèâ-
íîñòü, àíòèâèðóñíàÿ àêòèâíîñòü.
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